Cipesta®
Therapeutic Segment:
Antibacterial
Generic Name:
Ciprofloxacin HCl
Indication
Tablets
- 250MG
- 500MG
Suspensions
- 125MG/5ML
- 250mg/5ml
Injectables
- 200MG/100ML
In adults with:
- Lower respiratory tract infections due to Gram-negative bacteria: exacerbations of chronic obstructive pulmonary disease, broncho-pulmonary infections in cystic fibrosis or in bronchiectasis, pneumonia.
- Chronic suppurative otitis media.
- Acute exacerbation of chronic sinusitis especially if these are caused by Gram-negative bacteria
- Urinary tract infections
- Genital tract infections: gonococcal uretritis and cervicitis due to susceptible Neisseria gonorrhoeae, epididymo-orchitis including cases due to susceptible Neisseria gonorrhoeae and pelvic inflammatory disease including cases due to susceptible Neisseria gonorrhoeae.
- Infections of the gastro intestinal tract (e.g. travellers’ diarrhea)
- Intra-abdominal infections
- Infections of the skin and soft tissue caused by Gram-negative bacteria
- Malignant external otitis
- Infections of the bones and joints
- Prophylaxis of invasive infections due to Neisseria meningitidis
- Inhalation anthrax (post-exposure prophylaxis and curative treatment)
- Typhoid fever caused by Salmonella typhi.
May be used in the management of neutropenic patients with fever that is suspected to be due to a bacterial infection.
Indicated in children and adolescents with:
- Broncho-pulmonary i nfections in cystic fibrosis caused by Pseudomonas aeruginosa
- Complicated urinary tract infections and pyelonephritis
- Inhalation anthrax (post-exposure prophylaxis and curative treatment)